Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristin Wilson

Nurse Practitioner Cordova, TN Nurse Practitioner

NPI 1376792192 CMS profile 153349

146 Timber Creek Dr, Ste 200, Cordova, TN 38018

Open in the dashboard

General payments

$4,953

213 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristin Wilson of Cordova, TN is reported in the CMS Open Payments database as having received $4,953 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $586 18
2024 General $944 22
2023 General $858 28
2022 General $1,357 63
2021 General $1,208 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristin Wilson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kristin Wilson were reported at $586. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kristin Wilson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,208 $135 $40–$426 $132
2022 $1,357 $152 $48–$470 $149
2023 $858 $166 $54–$529 $160
2024 $944 $173 $55–$556 $164
2025 $586 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Protega Pharmaceutials LLC $651 6 payments
  2. Amgen Inc. $520 27 payments
  3. Nevro Corp. $469 6 payments
  4. Scilex Pharmaceuticals Inc. $396 28 payments
  5. Medtronic, Inc. $334 5 payments
  6. Abbott Laboratories $328 8 payments
  7. AbbVie, Inc. $315 32 payments
  8. Biohaven Pharmaceuticals, Inc. $287 15 payments
  9. Boston Scientific Corporation $268 7 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $216 16 payments
  11. Other $1,169 63 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,953 213 payments
Products named General payments · program years 2021–2025
  1. ROXYBOND $651 6 payments
  2. AIMOVIG $520 27 payments
  3. NURTEC ODT Primary Care $502 31 payments
  4. Omnia $378 4 payments
  5. ZTLido $355 25 payments
  6. INTELLIS ADAPTIVESTIM $334 5 payments
  7. UBRELVY $299 30 payments
  8. NURTEC ODT Pain $188 11 payments
  9. ZAVZPRET $175 10 payments
  10. Qutenza $165 8 payments
  11. Other $1,693 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

3,441

Median for Nurse Practitioner: 389

Drug cost

$187,358

Median for Nurse Practitioner: $21,885

Branded share of claims

52.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 31 $58,077
Aimovig Autoinjector Erenumab-Aooe Brand 18 $25,790
Buprenorphine Generic 104 $24,645
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 820 $19,126
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 760 $14,938
Lidocaine Generic 50 $10,133
Fentanyl Generic 84 $7,018
Gabapentin Generic 463 $6,316
Xtampza Er Oxycodone Myristate Brand 15 $5,276
Pregabalin Generic 132 $4,238

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $425
$425 — —
Qutenza
  • Averitas Pharma Inc. $76
$76 — —
NURTEC ODT
  • PFIZER INC. $44
$44 31 —
ZAVZPRET
  • PFIZER INC. $44
$44 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record